{"id":586205,"date":"2026-07-15T00:00:00","date_gmt":"2026-07-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0010-2026-biopharma-peripheral-arterial-disease-current-treatment-treatment-algorithms-claims-data-analysis\/"},"modified":"2026-07-16T11:19:46","modified_gmt":"2026-07-16T11:19:46","slug":"algocv0010-2026-biopharma-peripheral-arterial-disease-current-treatment-treatment-algorithms-claims-data-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocv0010-2026-biopharma-peripheral-arterial-disease-current-treatment-treatment-algorithms-claims-data-analysis\/","title":{"rendered":"Peripheral Arterial Disease &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Peripheral Artery Disease (US)"},"content":{"rendered":"<p>Peripheral artery disease (<abbr title=\"peripheral arterial disease\">PAD<\/abbr>) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication (pain, cramping, leg fatigue), and elevated risk of cardiovascular (<abbr title=\"cardiovascular\">CV<\/abbr>) events and limb complications, including amputation. This report focuses on <abbr title=\"peripheral arterial disease\">PAD<\/abbr> pharmacotherapy, which is intended to reduce the risk of <abbr title=\"cardiovascular\">CV<\/abbr> and limb events, manage symptoms, and improve functional status. The <abbr title=\"peripheral arterial disease\">PAD<\/abbr> treatment landscape is mature and largely dominated by generic therapies. Key drugs include antiplatelets, lipid-lowering, antihypertensives, and vasoactive therapies. In this report, we use patient-level claims data to analyze prescribing dynamics in the U.S. <abbr title=\"peripheral arterial disease\">PAD<\/abbr> market and provide insights into the factors shaping treatment patterns among newly diagnosed and recently treated patients.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"peripheral arterial disease\">PAD<\/abbr> patients?<\/li>\n<li>What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"peripheral arterial disease\">PAD<\/abbr> patients?<\/li>\n<li>How has low-dose rivaroxaban been integrated into the treatment algorithm, and what is its source of business?<\/li>\n<li>What percentage of <abbr title=\"peripheral arterial disease\">PAD<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"peripheral arterial disease\">PAD<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<ul>\n<li>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/li>\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Key drugs covered<\/strong><\/p>\n<p>Statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, aspirin, clopidogrel, rivaroxaban, <abbr title=\"angiotensin-converting enzyme\">ACE<\/abbr> inhibitors, <abbr title=\"angiotensin II receptor blocker\">ARB<\/abbr>s, cilostazol.<\/p>\n<p class=\"text-align-left\"><strong>Key analyses:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Brand \/ therapy usage across longitudinal patient sample<\/li>\n<li>Newly diagnosed patient analysis<\/li>\n<li>Treatment initiation and progression<\/li>\n<li>Line of therapy analysis<\/li>\n<li>Combination therapy analysis<\/li>\n<li>Source of business for recently treated patients<\/li>\n<li>Persistency and compliance analysis<\/li>\n<li>Product-level patient flow charts<\/li>\n<\/ul>\n<p><strong>Product <\/strong><strong>enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-586205","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-peripheral-arterial-disease","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/586205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=586205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}